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Busulfan (Bu) is widely used in conditioning regimens for infants undergoing allogeneic hematopoietic
progenitor cell transplantation (HPCT), but the best approach to administer Bu in this population is still
unknown. Here, we report a single-center experience of the use of a test dose to guide dose adjustment of
intravenous (i.v.) Bu therapy in infants. Between 2004 and 2013, 33 infants younger than 1 year with
nonmalignant conditions received allogeneic peripheral blood or cord blood HPCT after a reduced-intensity
conditioning (RIC) regimen consisting of ﬂudarabine, antithymocyte globulin, and 2 single daily doses of
i.v. Bu. Pharmacokinetic results of a test dose of i.v. Bu (.8 mg/kg) were used to determine the dose of 2 single
daily i.v. Bu regimen doses, adjusted to target an area under the curve (AUC) of 4000 mMol*minute per day in
a ﬁrst cohort (n ¼ 12) and 5000 mMol*minute in a second cohort (n ¼ 21). The mean Bu clearance in our infant
patients was found to be 3.67  1.03 mL/minute/kg, and the test dose clearance was highly predictive of the
regimen dose clearance. The mean AUC achieved after the ﬁrst single daily regimen dose was 3951  1239 in
the AUC 4000 cohort and 4884  766 for the AUC 5000 cohort. No patient in either cohort developed hepatic
sinusoidal obstructive syndrome or seizures attributable to Bu. Primary graft failure occurred in 4 patients
and secondary graft failure occurred in 3, predominantly in the AUC 4000 cohort (6 of 7). Among the
engrafted patients (n ¼ 28), 16 achieved full donor chimerism and 9 patients attained stable mixed chime-
rism. Overall survival of patients at 6 years after transplantation was 59.5% for the AUC 4000 cohort and 85.4%
for the AUC 5000 cohort, with primary graft failure in the ﬁrst cohort being a major contributor to morbidity.
Logistic regression analysis showed that the risk of graft failure increased signiﬁcantly if cord blood he-
matopoietic progenitor cells were used or if total Bu exposure was below 4000 mMol*minute per day for
2 days. The difference in clinical outcomes between the 2 cohorts supports the conclusion that targeting a
higher Bu AUC of 5000 mMol*minute per day for 2 days improves donor engraftment in infants with
nonmalignant conditions undergoing RIC HPCT without increasing toxicity. Measuring i.v. Bu pharmokinetics
using a test dose allows timely adjustment of single daily regimen doses and optimization of total Bu
exposure, resulting in an effective and safe regimen for these infants.
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Busulfan (Bu; Otsuka Laboratories, Japan) is a critical
component of many conditioning regimens used to prepare
infant patients for hematopoietic progenitor cell trans-
plantation (HPCT). The profound immunosuppressive effectedgments on page 1619.
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ty for Blood and Marrow Transplantation.young children, which can adversely affect growth and
development [1,2]. A patient’s total exposure to Bu is an
important parameter that guides its use: a higher-than-
optimal exposure predisposes the patient to the toxic ef-
fects of the drug, whereas a suboptimal exposure increases
the risk of graft failure [3]. The effective Bu exposure in pa-
tients who receive the drug could be highly variable,
particularly in young children [4]. Unpredictable pharmaco-
kinetic (PK) values are commonly seen after oral Bu doses in
children [5-7], as erratic intestinal absorption of oral Bu and
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variability in effective Bu exposure [7,8]. The increasing use
of an i.v. Bu formulation has partially addressed this
variability problem. One exception is in infant recipients, as
infants generally have a faster clearance of the drug, thereby
invalidating dosing conclusions drawn from i.v. Bu PK data
obtained in adults or older children [4]. The best clinical
strategy to ensure optimal Bu exposure in infants receiving
i.v. Bu is, hence, still unknown.
Most experience with the i.v. formulation of Bu has been
with the traditional 4-times daily dosing (16 doses) regimens
[8-10]. To optimize total Bu exposure in these regimens, PK
data are usually obtained after the ﬁrst regimen Bu dose and
then used to adjust the remaining doses [6,7]. More recently,
once daily and twice daily dosing schedules of i.v. Bu were
found to be safe and effective alternatives in patients with
hematological malignancies undergoing HPCT [11-14]. To
ensure an optimal Bu exposure with the single daily dosing
schedule, a small i.v. Bu test dose is given several days before
the administration of the regimen doses. The collection and
analysis of 4 or 5 blood samples after the test dose has been
shown to provide reproducible PK values that allow timely
adjustment of the regimen Bu doses [11]. This ﬁnding con-
ﬁrms previous sampling strategies for pharmacokinetically
directed dosing with high-dose i.v. Bu in HPCT preparative
regimens [15]. Several other studies in adult patients have
similarly demonstrated that conditioning regiments using
once or twice daily i.v. Bu, coupled with a dose-adjustment
strategy, were relatively well tolerated and showed predict-
able Bu blood concentrations [9,11-13].
Our group has previously reported the feasibility of using
a test dose followed by 2 single daily doses of i.v. Bu as part of
a reduced-intensity conditioning (RIC) regimen for pediatric
patients [4,14]. To develop and validate a clinical strategy to
optimally administer i.v. Bu to infant transplantation pa-
tients, we undertook a clinical study to assess the PK of test
and single daily regimen doses of i.v. Bu in infants with
nonmalignant diseases. We hypothesized that using a test
dose of i.v. Bu to obtain a PK proﬁle for each patient before
transplantation would enable more accurate targeting of
total Bu exposure and result in better donor engraftment and
decreased toxicity. There are no previously reported clinical
studies examining the administration procedure, feasibility,
and efﬁcacy of single daily dose i.v. Bu for infants undergoing
HPCT. This paper provides useful information that can guide
HPCT conditioning using single-dose i.v. Bu in this unique
patient population.
PATIENTS AND METHODS
Patient Enrollment
Patients in this study were infants less than 1 year of age with
nonmalignant diseases, who participated in a RIC allogeneic HPCT protocol
at the Ann & Robert H. Lurie Children’s Hospital of Chicago (formerly Chil-
dren’s Memorial Hospital) between 2004 and 2013. These infants under-
went allogeneic HPCT after receiving a single daily dose i.v. Bu conditioning
regimen. All patients had disease diagnosis conﬁrmed by histology, enzyme,
or genetic testing before the start of treatment. Informed consent for
participation on this protocol was given by their parents in compliance with
the policies of the institutional review board.
Treatment Regimen
Patients were enrolled on an RIC HPCT protocol developed at this
institution [14]. The RIC regimen included a single test dose (.8 mg/kg) of i.v.
Bu given over 3 hours on day 10, ﬂudarabine 30 mg/m2/day on days 10
to5, 2 single daily doses of i.v. Bu on days5 and4 (as a 3-hour infusion),
and rabbit antithymocyte globulin (ATG) 2 mg/kg/day on days 4 to1. The
single daily regimen doses of i.v. Bu were adjusted to target area under the
curve (AUC) of 4000 mMol*minute per day in a ﬁrst cohort of patients and5000 mMol*minute per day in a second cohort (see below). For 4 patients
who received cord blood in the second cohort, a dose of thiotepa (5 mg/kg)
was administered on day 5.
Allogeneic hematopoietic progenitor cells (HPC) were infused on day 0.
The choice of HPC source depended on donor availability. The acceptable
HLAmismatches were 1 of 8 allele loci for peripheral blood HPC and 2 of
6 antigenic loci for cord blood HPC. All patients received prophylaxis against
graft-versus-host disease (GVHD) using mycophenolate mofetil and cyclo-
sporine A for 1 and 3 months after transplantation, respectively.
PK Studies of Bu Test and Regimen Doses
PK studies were performed after the Bu test dose to determine the
regimen dose to be administered and repeated after the ﬁrst single daily
regimen dose to measure the total Bu exposure, evaluated as the plasma
concentration-time AUC. Blood samples for the test dose studies were
collected at hour 3, 3.5, 5, and 7 after the completion of drug infusion. Blood
samples for the ﬁrst regimen dose were collected at hour 3, 3.5, 5, 8, and 24,
with the 24-hour sample drawn before the start of the second regimen dose.
Blood samples were placed on wet ice and processed within 1 hour after
collection. Plasma was separated by centrifugation at 2500 rpm for
10 minutes at 4C. Plasma was split into 2 equal amounts in 2 separate
cryovials and stored at 20C until the complete set of blood samples for
each dose was obtained. The samples were shipped to the Seattle Cancer
Care Alliance Clinical Pharmacokinetics Laboratory for determination of Bu
AUC and clearance [4].
Calculation of Bu AUC, Clearance, and Dose Adjustment
Bu PK parameters were calculated by ﬁtting a biexponential equation
with the RSTRIP program (MicroMath, Salt Lake City, UT) to the data [13].
AUC was calculated by trapezoidal approximation and extrapolation based
on computer-generated parameters from time 0 to inﬁnity. The clearance
was calculated using the dose given divided by the weight times AUC. Based
on these parameters of the test dose, the regimen dose was adjusted to
target an optimal AUC (4000 or 5000 mMol*minute per day depending on
the cohort) for single daily dose administration. The following formula was
used in the dose adjustment: regimen dose to be given in mg ¼ 4000 or
5000 mMol*minute  (test dose given in mg/rest dose AUC achieved in
mMol*minute) [4].
Supportive Care
Lorazepan .05 mg/kg daily was administered for anticonvulsant pro-
phylaxis 2 hours before starting i.v. Bu. Antiyeast prophylaxis (ﬂuconazole, 3
to 5 mg/kg/day) was started with the conditioning therapy and continued
until day þ100. Anti-herpes prophylaxis (acyclovir, 250 mg/m2/dose) was
administered twice each day beginning on day 5 and continued until
day þ100. Anti-Pneumocystis jirovecii prophylaxis, (pentamidine, 4 mg/kg
i.v.) was administered on day 1 and every 30 days up to 6 months after
transplantation or 3 months after the cessation of immunosuppressive
therapy. Patients received i.v. immune globulin (400 mg/kg) every 3 weeks
through day þ100. After day þ100, immune globulin was administered to
maintain serum IgG levels > 400 mg/dL.
Donor Engraftment and Chimerism Analysis
Donor chimerism after HPCT was assessed by variable-number tandem
repeat or short tandem repeat polymorphism analysis, using genomic DNA
isolated from peripheral blood samples. Donor chimerism was evaluated
weekly after initial engraftment until the chimerism reached stability and
then followed at regular intervals as clinically indicated. Full donor
chimerism was deﬁned as donor contribution > 95% and mixed donor
chimerism as donor contribution between 5% and 95%. Primary graft failure
was deﬁned as the absence of absolute neutrophil counts recovery > 500
cells per mL by day þ28 and day þ42 for peripheral blood and cord blood
HPCT, respectively. Secondary graft failurewas deﬁned as a progressive loss
in donor chimerism after initial engraftment, with a cumulative decline of
w20% or more on 3 consecutive studies. In patients with severe combined
immunodeﬁciency, T cellespeciﬁc donor chimerism was be used in the
deﬁnition.
Statistical Analysis
Statistical analyses were performed using software programs from the
GraphPad Prism (San Diego, CA) and the R statistical packages. A t-test,
paired t-test, Fisher exact test, or Pearson correlation test was used to
compare data where appropriate. Survival curves were produced using the
product limit method of Kaplan and Meier and the survﬁt program, and
log-rank test was performed using survdiff program. In the analysis of
event-free survival (EFS), major events are deﬁned to include primary graft
failure, secondary graft failure, and death.
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Patient Characteristics
Thirty-three infants were treated between January
2004 and June 2013. Patients’ clinical proﬁles and char-
acteristics are summarized in Tables 1 and 2. There were
23 male and 10 female patients. The mean age at the time
of transplantation was 176  101 days. The mean weight
was 6.0  2.2 kg. All patients were diagnosed with
nonmalignant conditions, including severe combined
immune deﬁciency (n ¼ 17), Wiscott-Aldrich syndrome
(n ¼ 4), major histocompatibility complex II deﬁciency
(n ¼ 3), and 1 of each for the following diagnoses:
Gaucher disease, Krabbe disease, Omenn syndrome,
NEMO syndrome, osteopetrosis, reticular dysgenesis, IPEX
(immune dysregulation, polyendocrinopathy, enteropa-
thy, X-linked) syndrome, IPEX-like syndrome, and
mucopolysaccharidosis-1. Eight patients had related
donors and 25 had unrelated donors. Twenty patients
received peripheral blood HPC, 12 received cord blood,
and 1 received bone marrow as the source of HPC. The
median number of CD34þ HPC infused was .69 and 8.18 
106/kg for patients who received cord blood and noncord
blood, respectively (range, .11 to 3.65 and 1.56 to 19.67,
respectively). Among the 12 patients who received
cord blood, only 1 (patient number 13) received a cell
dose that was below the recommended number of .17 
106/kg [16].Table 1
Patient Clinical Proﬁles
No. Type of Donor/Stem
Cell Source
CD34 Cell
Dose,  106/kg
HLA Loci
Match
Age at
HSCT, d
Diagnos
1 UCB .71 5:6 212 SCIDs
2 MMRD/PBSC 3.40 6:10 107 Gauche
3 UCB 2.78 5:6 338 SCIDs
4 UCB 2.29 5:6 267 SCIDs
5 UCB .55 4:6 66 SCIDs
6 UCB .27 6:6 20 Krabbe’
7 MRD/PBSC 7.00 8:10 126 SCIDs
8 MMRD/PBSC 9.37 10:10 306 IPEX-lik
syndrom
9 MSD/PBSC 3.29 10:10 190 NEMO
10 MSD/PBSC 1.56 6:10 103 Omenn
11 MMRCB .69 6:10 35 SCIDs
12 UCB 3.65 5:6 33 SCIDs
13 UCB .11 6:6 227 IPEX
14 MSD/PBSC 5.85 10:10 187 SCIDs
15 MUD/PBSC 9.40 10:10 271 WAS
16 MUD/PBSC 15.50 10:10 142 SCIDs
17 MSD/PBSC 11.97 10:10 158 RD
18 MUD/PBSC 9.67 7:10 107 SCIDs
19 MUD/PBSC 10.70 9:10 179 SCIDs
20 MSD/marrow 19.67 10:10 309 Osteope
21 MUD/PBSC 4.01 9:10 265 MPS-1
22 MSD/PBSC 6.20 10:10 188 MHC cla
23 UCB .47 4:6 351 WAS
24 UCB .58 5:6 157 SCIDs
25 MRD/PBSC 6.00 10:10 181 MHC cla
26 MUD/PBSC 5.39 8:10 327 WAS
27 MUD/PBSC 6.00 9:10 102 SCIDs
28 MSD/PBSC 6.00 10:10 36 SCIDs
29 UCB .91 5:6 331 MHC cla
30 MUD/PBSC 6.00 10:10 69 SCIDs
31 MUD/PBSC 6.00 10:10 30 SCIDs
32 UCB ND 6:6 150 WAS
33 MSD/PBSC 6.92 10:10 229 SCIDs
UCB indicates unrelated cord blood; SCID, severe combined immune deﬁciency; ND
stem cells; GF, graft failure; A/w, alive and well; MRD, matched related donor; I
drome; MSD, matched sibling donor; NEMO, NF-kappa B essential modulator; MM
Wiskott-Aldrich syndrome; RD, reticular dysgenesis; MPS-1, mucopolysaccharidos
Patients number 1 through 12 received Bu targeted to AUC of 4000, and patientsPK Evaluation of Bu Test Dose
The resultsof thePKevaluationare showninTable3. Thirty-
one patients received a test dose of i.v. Bu, .8 mg/kg, 5 days
before theﬁrst Bu regimendose; 2patients received a test dose
of 1 mg/kg (patients number 3 and 5). Test dose PK samples
from 29 of 33 patients yielded informative results. The mean
clearance of the Bu test dose was 3.67  1.03 mL/minute/kg.
The Bu clearance did not show signiﬁcant correlationwith the
age of the infants (Pearson’s correlation coefﬁcient r¼ .05, 95%
conﬁdence interval [CI], .32 to .41, P ¼ .77) (Figure 1A). The
mean Bu test dose AUC achievedwas 963 299 mMol*minute.
The AUCachievedwaswithin 10%of an expected value of 1000
mMol*minute for 34% of patients (n¼ 10) and between10%and
30% for 45% of patients (n¼ 13). Three patients (10%) had a Bu
test dose AUC that deviated from the expected value by> 50%
(patient number 6 had a low AUC at 439 mMol*minute and
patients number 10 and 22 had high AUCs at 1828 and 1748
mMol*minute, respectively). The coefﬁcient of variation (stan-
dard deviation/mean) for the Bu test dose AUC achieved was
31%, indicating thatBubioavailability inour infantpatientswas
still variable despite the use of an i.v. formulation and that a
regimen dose adjustment strategy could be beneﬁcial.
Adjustment of Bu Regimen Dose and Targeting of Total Bu
Exposure
The PK results of the Bu test dose were used to determine
the single daily i.v. Bu regimen doses that target a desiredis Busulfan
AUC Achieved
Outcome Event/Follow-up, d
ND Died þ727
r 3527 Died, primary GF þ337
3560 A/w þ3284
2912 A/w þ3165
ND Died, primary GF þ65
s 7254 A/w, secondary GF þ147
3663 A/w þ2899
e
e
3664 A/w, secondary GF þ222
4381 A/w, secondary GF þ265
’s 3977 A/w þ2724
2916 Died, primary GF þ64
3663 A/w þ2612
3719 A/w, primary GF þ28
4924 A/w þ2402
4825 A/w þ2250
4636 A/w þ2213
4508 A/w þ2199
5149 A/w þ2186
5679 A/w þ2164
trosis 4551 A/w þ2157
4799 A/w þ2032
ss II 7606 A/w þ1877
5050 Died, bleeding þ14
4238 A/w þ1451
ss II 4758 Died, respiratory failure þ17
5018 A/w þ1213
4869 A/w þ1148
5076 A/w þ939
ss II 5008 A/w þ680
4796 Died, PLTD þ118
5332 A/w þ541
3996 A/w þ239
4035 A/w þ161
, not determined; MMRD, mismatched related donor; PBSC, peripheral blood
PEX, immunodysregulation polyendocrinopathy enteropathy X-linked syn-
RCB, mismatched related cord blood; MUD, matched unrelated donor; WAS,
is; PLTD, post-transplantation lymphoproliferative disease.
number 13 through 33 received Bu targeted to AUC 5000.
Table 2
Patient Characteristics
Patient Characteristic Total (N ¼ 33) Cohort 1 AUC Target
4000 (n ¼ 12)
Cohort 2 AUC Target
5000 (n ¼ 21)
P Value
Sex (M/F) 23/10 9/3 14/7 .71
Age, mean (SD), d 176 (101) 150 (111) 180 (95) .28
Weight, mean (SD), kg 6.0 (2.2) 5.3 (2.1) 6.5 (2.1) .12
PID disease (%) 29 (88%) 10 (83%) 19 (90%) .61
SCID (%) 19 (58%) 8 (67%) 11 (52%) .49
Sibling donor (%) 8 (24%) 2 (17%) 6 (29%) .68
Cord blood (%) 12 (36%) 7 (58%) 5 (24%) .06
CD34 cell dose, mean (SD), 106/kg 5.4 (4.7) 3.0 (2.8) 6.9 (5.0) .008
Cord blood 1.18 (1.17) 1.56 (1.33) .52 (.33) .09
Nonecord blood 7.62 (4.22) 4.92 (3.18) 8.46 (4.23) .08
M indicates male; F, female; PID, primary immunodeﬁciency.
J. Ward et al. / Biol Blood Marrow Transplant 21 (2015) 1612e1621 1615level of total Bu exposure. In a ﬁrst cohort of 12 patients
(patient number 1 to 12), the Bu AUC was targeted to be
4000 mMol*minute per day for 2 days. Because interim
analysis revealed that 3 patients in this cohort developed
primary graft failure and 3 developed secondary graft failure
(see below), the targeted Bu AUC was increased to 5000
mMol*minute per day for 2 days in a second cohort of
21 patients (patient number 13 to 33). In addition, in the
second cohort, the use of cord blood was restricted to those
for whom peripheral blood stem cell sources were not
available, and thiotepa, 5 mg/kg i.v. given once, was added to
the conditioning regimen for the patients who received cord
blood (patients number 23, 24, 29, and 32). The 2 cohorts
were chronologically different: patients in the ﬁrst cohort
(AUC 4000) were treated between 2004 and 2006 and those
in the second cohort (AUC 5000), between 2007 and 2013.
Patients in the 2 cohorts have similar characteristics, except
for the AUC target and the percentage of cord blood use
(Table 2).
The dose adjustment strategy described above was used
to determine the Bu regimen dose for each patient (Table 3).
Bu regimen doses lower than 3.2 mg/kg/dose were admin-
istered to 5 infants (2 infants in the AUC 4000 cohort and 3 in
the AUC 5000 cohort) and doses higher than 3.2 mg/kg/dose
were administered to 26 infants (8 infants in the AUC 4000
cohort and 18 in the AUC 5000 cohort). Two patientsTable 3
Bu Test Dose and Regimen Dose PK Data
Bu PK Parameter Total (N ¼ 33) Coh
400
Bu test dose PK data, mean (SD)
Test dose by weight, mg/kg .8
Test dose, mg 5.0 (1.8) 4
Test dose clearance, mL/min/kg 3.7 (1.0) 4
Test dose AUC, mMol*min 963 (299) 90
Bu regimen dose adjustment, n (%)
Dose decreased 5 (15%)
Dose increased 26 (79%)
AUC unavailable 2 (6%)
Bu regimen dose PK data
Regimen dose by weight, mg/kg 4.2 (1.2) 3
Regimen dose, mg 25.9 (12.7) 19
Regimen dose clearance 3.8 (1.0) 3
Regimen dose AUC, mMol*min 4584 (1029) 395
Deviation from AUC target, n (%)
Regimen dose AUC unavailable 2 (6%)
<10% AUC deviation 22 (66.7%)
10-30% AUC deviation 7 (21.2%)
31-50% AUC deviation 0
>50% AUC deviation 2 (6%)
* Two patients in cohort 1 received test doses of 1 mg/kg.(patients number 1 and 2) received single daily regimen
doses of 3.2 mg/kg/dose because PK data were unavailable.
The mean adjusted single daily Bu regimen dose for the
entire group of 33 infants was 4.2  1.2 mg/kg. In the ﬁrst
cohort (AUC 4000), the mean regimen dose was 3.8  1.2
mg/kg/dose (range 1.8 to 6.6). In the second cohort (AUC
5000), the mean regimen dose was 4.5  1.1 mg/kg/dose
(range 2.7 to 7.1). The 3 outliers who had large deviations in
test dose AUC (patients number 6, 10, and 22, see above) had
major dose adjustments (1 patient adjusted upward and
2 patients, downward) and received regimen doses of 6.6,1.8,
and 3.17 mg/kg/dose, respectively.
PK Evaluation of Bu Regimen Dose
To determine the effectiveness of the regimen dose
adjustment strategy described above, PK studies were per-
formed after the ﬁrst single daily Bu regimen dose. Evalu-
able PK results were available for 31 patients (all except
patients number 1 and 5). The Bu clearance of the ﬁrst
regimen dose was 3.77  1.03 mL/minute/kg for the entire
group (Table 3). No difference was found in the clearances
amongst the ﬁrst and second cohorts (3.84  .97 mL/min-
ute/kg and 3.74 1.07 mL/minute/kg, respectively; P ¼ .82).
Comparison of the Bu clearance rates after the test and
regimen doses in individual patients showed good corre-
lation between the 2 rates (r ¼ .71; 95% CI, .46 to .85;ort 1 AUC Target
0 (n ¼ 12)
Cohort 2 AUC Target
5000 (n ¼ 21)
P Value
.8* .8 d
.4 (2.0) 5.4 (1.7) .17
.2 (1.5) 3.5 (.75) .10
1 (413) 987 (252) .50
2 (16.7%) 3 (14.3%)
8 (66.7%) 18 (85.7%)
2 (16.7%) 0
.8 (1.2) 4.5 (1.1) .10
.8 (10.8) 29.3 (12.9) .045
.8 (1.0) 3.7 (1.1) .82
2 (1240) 4884 (776) .016
2 (16.7%) 0
7 (58.3%) 15 (71.4%)
2 (16.7%) 5 (23.8%)
0 0
1 (8.3%) 1 (4.8%)
Figure 1. Bu clearance in infants. (A) Test dose Bu clearance plotted as a function of age, showing no statistically signiﬁcant dependence on age. (B) Regimen dose Bu
clearance plotted against test dose Bu clearance, showing excellent correlation between the 2. (C) Regimen dose Bu clearance plotted as a function of age, showing no
statistically signiﬁcant dependence on age.
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there was no correlation between age and Bu regimen dose
clearance (r¼ .32, P¼ .08) (Figure 1C). The mean Bu regimen
dose AUC achieved was 3952  1240 mMol*minute for the
ﬁrst cohort (target AUC 4000) and 4884  776 mMol*minute
for the second cohort (target AUC 5000). The difference
between the AUC achieved in the 2 cohorts was statistically
signiﬁcant (t-test, P ¼ .016), indicating that the test dos-
eebased Bu adjustment strategy effectively targeted
different levels of Bu exposure for the 2 cohorts as planned.
The Bu AUC achieved was within 10% of the AUC target for
65% of patients (n¼ 20) and between 10% and 30% for 29% of
patients (n ¼ 9). Two patients (6%) had a Bu regimen dose
AUC that deviated from the desired target by > 50%
(patients number 6 and 22). Of interest, patient number 6,
who was a outlier with too low a test-dose AUC (see above),
now had too high a regimen-dose AUC (7254 mMol*minute)
after an upward dose adjustment, whereas patient 22, who
had a high test-dose AUC, still had a high regimen-dose AUC
(7606 mMol*minute) after a downward dose adjustment. A
third outlier with a high test-dose AUC (patient 10) had an
optimal regimen-dose AUC (3977 mMol*minute) after a
downward dose adjustment. The coefﬁcients for variation
for the AUC achieved were 31.3% and 15.9% for the ﬁrst and
second cohort, respectively, indicating that the Bu dose
adjustment strategy successfully decreased the interpatient
PK variability in the second cohort, but in individual
patients, the AUC achieved could still be variable.Table 4
Transplantation Toxicities and Outcomes
Parameter Total (N ¼ 33) Coh
400
Engraftment 28 (85%) 9 (7
Primary graft failure 4 (12%) 3 (2
Secondary graft failure 3 (9%) 3 (2
Primary or secondary graft failure 7 (21%) 6 (5
Full donor chimerism 16 (48%) 4 (3
Stable mixed donor chimerism 9 (27%) 2 (1
Mucositis grade II-IV 0 0
SOS 0 0
Seizure 0 0
Transplantation-related mortality* 1 (3%) 0
Acute GVHD grade I-II 7 (21%) 2 (1
Acute GVHD grade III-IV 0 0
Chronic GVHD limited 1 (3%) 0
Chronic GVHD moderate-severe 0 0
Data presented are n (%), unless otherwise indicated.
* Excluding graft failure.Donor Engraftment and Chimerism
Engraftment data are presented in Table 4. One patient
died from a complication of his underlying disease before
engraftment (patient number 23, see below). Twenty-eight
patients (85%) had neutrophil recovery with an absolute
neutrophil count > 500 by post-transplantation day þ28
(peripheral stem cells) or dayþ42 (cord blood). Four patients
(12%) experienced primary graft failure either with no re-
covery of neutrophil counts or with recovery of autologous
blood cells (patients number 2, 5, 11, and 13). Three patients
(10%, patients number 6, 8, and 9) initially achieved post-
transplantation engraftment but subsequently experienced
secondary graft failure, with signiﬁcant drops in donor
chimerism more than 4 months after their transplantation
(see below). Except for patient number 13, all patients with
primary and secondary graft failure belonged to the ﬁrst
cohort with a target Bu AUC of 4000. The rate of primary or
secondary graft failure in the ﬁrst cohort (AUC 4000) was 50%
and that in the second cohort (AUC 5000) was 9% (chi-
square, 20.58; df¼ 3; P¼ .0001). Three patients with primary
graft failure and 3 with secondary graft failure each subse-
quently underwent a second transplantation using HPC from
either an alternative or the same donor.
The levels of donor chimerism in the engrafted patients
were followed at regular intervals after the recovery of white
cell counts. Of the 28 patients who engrafted, 16 (57%) ach-
ieved stable full donor chimerism with donor cells > 95%
(4 of 9 patients in the ﬁrst cohort and 12 of 19 patients in theort 1 AUC Target
0 (n ¼ 12)
Cohort 2 AUC Target
5000 (n ¼ 21)
P Value
5%) 19 (90%) .13
5%) 1 (5%) .28
5%) 0 .049
0%) 1 (5%) .007
3%) 12 (57%) .28
7%) 7 (33%) .43
0 d
0 d
0 d
1 (5%) d
7%) 5 (24%) d
0 d
1 (5%) d
0 d
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donor chimerism (5 of 9 in the ﬁrst cohort and 7 of 19 in the
second). Among these patients, 9 (32%) had stable mixed
chimerism at long-term follow up, with a mean value of
61.6  29.9%, whereas 3 subsequently developed secondary
graft failure. These 3 latter patients achieved the highest
level of total donor chimerism of 45%, 87%, and 59% on
post-transplantation day 25, 41 and 27, respectively, but the
chimerism progressively declined to a low of 28%, 16%, and
19% at day 137, 216, and 238, respectively, at which time
the patients proceeded to receive infusion of additional
donor HPC.
Regimen-Related Toxicity and Survival
Transplantation toxicities and outcomes are summarized
in Table 4. The conditioning regimen was well tolerated.
Several patients had temporary decreases in appetite or oral
intake around the time of conditioning, but no patient
developed grade II to IV mucositis. No patients experienced
ﬂuid retention, excessive weight gain, or elevated bilirubin
compatible with hepatic sinusoidal obstructive syndrome
(SOS), including patients in the second cohort, who were
exposed to a higher amount of Bu. No patient developed
seizures attributable to Bu administration. One patient
(number 22) developed a seizure on post-transplantation
day þ14, presumably related to cyclosporine and not Bu
toxicity. Seven patients experienced grades I and II acute
GVHD: 2 in cohort 1 (AUC target of 4000) and 5 in cohort 2
(AUC 5000). No patients in either cohort experienced grades
III and IV acute GHVD. One patient in the second cohort
(patient number 24) had limited chronic GVHD of the skin,
which responded promptly to topical steroid treatment. No
patients in either cohort developed moderate-to-severe
chronic GVHD. No deaths were attributed to either acute or
chronic GVHD. There is no statistically signiﬁcant difference
in GVHD rates between the ﬁrst and second cohort.
Seven patients in the study did not survive after their
transplantation; 4 in the ﬁrst cohort (AUC 4000) and 3 in
the second cohort (AUC 5000). In the ﬁrst cohort, patient
number 1 initially did well after receiving the transplant but
died at home on day þ727 from a nonmedical cause. Patient
number 2, who experienced primary graft failure and
received a second transplant, died on day þ337 from asso-
ciated complications. Patients number 5 and 11 experienced
primary graft failure and died from infection and multi-
system failure at day þ65 and þ64, respectively. In the sec-
ond cohort, 2 patients died from complications from their
underlying disease before engraftment. Patient number 23,
who had Wiskott-Aldrich syndrome and refractory throm-
bocytopenia, died on post-transplantation day þ14 of an
intracranial hemorrhage. Patient number 25, who had res-
piratory failure from an H1N1 inﬂuenza infection that pre-
dated the diagnosis of MHC class II deﬁciency, died on
day þ17 from progressive respiratory failure. A third patient
(number 30), who had X-linked SCID, developed Epstein-
Barr viremia and post-transplantation lymphoproliferative
disease (systemic and intracranial) 3 months after trans-
plantation and died on day þ118. Overall, the main cause of
death in cohort 1 was related to primary graft failure (n ¼ 3),
whereas the main cause of death in cohort 2 was related to
complications from their underlying diseases (n ¼ 2).
Twenty-six (79%) of the infants in this study are currently
alive and well with a median follow-up of 6.0 years (2192
days; range, 161 to 3284 days). Kaplan-Meier analysis
revealed an overall survival (OS) rate of 76.5% for the entiregroup of infants (95% CI, 62.4% to 93.7%), 59.5% for cohort
1 (target AUC 4000; 95% CI, 34.9% to 100%), and 85.4% for
cohort 2 (target AUC 5000; 95% CI, 71.5% to 100%). Analysis of
the occurrence of major events (primary graft failure, sec-
ondary graft failure, and death) revealed an EFS of 65.4% for
the entire group (95% CI, 50.7% to 84.4%), 41.7% for cohort
1 (95% CI, 21.3% to 81.4%), and 81.0% for cohort 2 (95% CI,
65.8% to 99.6%). The differences in OS and EFS between the
2 cohorts were nevertheless not statistically signiﬁcant (log
rank test, P¼ .24 and .057, respectively). Because 2 patients in
cohort 2 (patients number 23 and 25) died early from com-
plications of underlying diseases unrelated to the trans-
plantation, the survival analysis was repeated after exclusion
of these 2 patients. In the revised analysis, the OS rate was
found to be 81.4% for the entire group (95% CI, 67.7% to 97.8%),
59.5% for cohort 1 (95% CI, 34.9% to 100%), and 94.4% for
cohort 2 (95% CI, 84.4% to 100%) (Figure 2A,B). Analysis of
major events in the revised cohorts revealed EFS of 69.6% for
the entire group (95% CI, 54.8% to 88.5%), 41.7% for cohort
1 (95% CI, 21.3% to 81.4%), and 89.5% for cohort 2 (95% CI,
76.7% to 100%) (Figure 2C,D). Log-rank analysis revealed that
the differences in OS and EFS between the revised cohorts
were statistically signiﬁcant (P¼ .037 and .009, respectively).
Risk of Graft Failure and Level of Bu Exposure
Because graft failure appeared to be a factor that signiﬁ-
cantly affected our patients’ outcome, we analyzed the
relationship between the risk of graft failure and the level of
Bu exposure or other transplantation parameters. Univariate
analysis showed that there was no statistically signiﬁcant
correlation between graft failure and variables such as
weight, sex, underlying diseases, use of related donors, use of
cord blood, Bu clearance, and Bu regimen-dose AUC achieved
(data not shown). Analysis of patient subgroups, however,
showed a correlation between the risk of graft failure and the
Bu regimen-dose AUC achieved, when patients were strati-
ﬁed by cord blood versus nonecord blood use. For the pa-
tients who received cord blood, there was a high rate of graft
failure overall (4 of 12 patients), regardless of the level of Bu
AUC achieved. In contrast, for the patients who received
nonecord blood HPC, 3 of 6 patients who had AUC < 4500
mMol*minute experienced graft failure, whereas 0 of 15 pa-
tients who had AUC  4500 mMol*minute experienced graft
failure, a difference that was statistically signiﬁcant by the
Fisher exact test (P ¼ .015). These results indicated that for
the patients who received cord blood, the risk of graft failure
was so high that the level of Bu exposure became irrelevant,
whereas for the patient who received peripheral blood HPC,
the risk of graft failure increased markedly when the total Bu
exposure fell below w4500 mMol*minute per day.
DISCUSSION
Bu-based conditioning regimens are commonly used in
HPCT for infants, but the best Bu administration parameters
to use to improve outcome and minimize toxicity in this
population are still unclear. Several factors associated with
Bu, such as an age-dependent PK variability, a narrow ther-
apeutic index, the recent availability of an i.v. formulation,
and the more frequent use of single daily dose administra-
tion schedules, have to be taken into consideration when
deciding on the most appropriate way to administer Bu to
infants before they receive HPCT.
Two major problems associated with the use of oral Bu in
pediatric patients are the nonretention of the drug because of
vomiting and the unpredictable bioavailability because of
Figure 2. Survival of infants after transplantation. (A) Overall survival (OS) of patients who underwent transplantation plotted against number of days after
transplantation. Two patients who died early from their underlying diseases were excluded from the analysis (see text). Dashed curves indicate the 95% conﬁdence
intervals. (B) OS of patient cohorts based on Bu AUC targets. (C) Event-free survival (EFS) of patients who underwent transplantation, excluding the 2 patients with
early deaths. Events include primary graft failure, secondary graft failure, and death. Dashed curves indicate the 95% conﬁdence intervals. (D) EFS of patient cohorts
based on Bu AUC targets.
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bioavailability of orally administeredBu in childrenwas found
to vary as much as 5 fold [5] along with a 6- to 20-fold vari-
ation in apparent clearance [17-19]. An i.v. Bu formulation
could potentially avert these issues [6,20]; but, even with an
i.v. formulation, the variable Bu clearance rate in individual
patients could result in either an inadequate or excessive
systemicdrugexposure. The issueof BuPKvariabilitycouldbe
worse in infants and, if not properly addressed, could increase
the risk of graft rejection or regimen-related toxicity [8,9,11].
For these reasons, various strategies, such as dosing by
weight-based nomograms [21] or individualized dosing
based on plasma Bu level monitoring [22], have been used to
target an optimal Bu exposure for each patient.
In conditioning regimens in which Bu was given 4 times
each day for 4 days, results of PK analysis after the ﬁrst Bu
dose were usually employed to guide dosing of subsequent
doses. With the use of 2 single daily doses of Bu in more
recent RIC conditioning regimens, this practice becomes
infeasible. To address this issue, we evaluated the strategy ofthe use of a test dose of i.v. Bu several days before the
regimen dose. We hypothesized that this Bu test dose
strategy will enable the establishment of individual Bu
clearance rate in each patient, which can then be used to
adjust the regimen doses and optimize total Bu exposure.
Our data show that the Bu clearance measured after the
test dose was highly predictive of the clearance of subse-
quent regimen doses (Figure 1B). The use of the test dose
information to adjust the regimen doses led to an improve-
ment of the Bu exposure achieved, with 65% of patients
achieving a Bu exposure within 10% of the intended AUC
target and 94% within 30%. Other than 2 patients for whom
test dose PK data were not available, all other patients in our
study received either an upward or downward adjustment
after the test dose to achieve the total AUC desired, indicating
the practicality of the use of the test dose PK results to
optimize total Bu exposure. The test doseebased Bu adjust-
ment strategy described thus represents a rational and
effective way to address the problem of high variability
associated with Bu administration [23].
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infants are limited. Published reports have suggested that the
bioavailability of i.v. Bu in young children could be signiﬁ-
cantly lower than that in adults [24-29]. This decreased
bioavailability could be the result of increased Bu clearance
in children, as was described after the administration of oral
Bu [25,30,31]. In previous reports, the total body clearance
of Bu in infants was estimated to be between 3.6 and
3.9 mL/minute/kg [28,32,33]. In our study, the Bu clearance
rate for infants was found to be 3.68  1.03 mL/minute/kg, in
agreement with these reports. Nevertheless, we did not
detect a decline in Bu clearance in infants younger than
6 months, as suggested by some studies [32]. When the Bu
test dose clearance values were used to adjust Bu regimen
doses to target an AUC of 5000, they translated to adjusted
regimen doses of 4.5  1.1 mg/kg/day. These doses were
signiﬁcantly higher than the 3.2 mg/kg/day “standard” doses
normally given in regimens that administer Bu for 4 days
[28], but because Bu is only administered for 2 days in our
RIC regimen, the total Bu dosage given to our patients was
only 70% of that in a “standard” Bu-containing regimen.
An important question to answer in our study is how this
lower level of Bu exposure correlated with regimen-related
toxicities. In our patients, the combination of ﬂudarabine,
2 single daily doses of i.v. Bu, and ATG as the conditioning
regimen was not found to cause SOS, severe mucositis, or
seizuredcomplications often associated with Bu adminis-
tration. The development of SOS has been postulated to be
related to the level of Bu exposure. In adults, total Bu expo-
sure above 24,000 mMol*minute was linked to a higher risk
of SOS development [5,34,35]. In pediatric patients who
received Bu in the setting of myeloablative conditioning, the
incidence of SOS ranges between 10% and 30% [33,36-38],
even though the relationship between SOS and a high level of
Bu exposure was less clearly established [33,38,39]. In our
patients, Bu was only given for 2 days and total Bu exposure
(a total AUC target of 10,000 mMol*minute) was far below
this proposed threshold associated with the development of
SOS. In addition, no cyclophosphamide was used in our
conditioning regimen. These factors could explain the
absence of SOS in our patients. The incidence of mucositis
was also very low in our patients, presumably related to the
low Bu exposure they received. Similarly, only 1 of our pa-
tients developed seizure, likely caused by cyclosporine
toxicity, which is in line with the low risk of Bu-induced
seizure reported in children [40]. The rate of acute or
chronic GVHD development was also very low in our study,
in contrast to other studies of infants who underwent HPCT
[41]. This low GVHD rate could be related to the decreased
inﬂammatory stimuli associated with our RIC regimen,
which avoided triggering excessive cytokine release [42].
Because our patients only received 2 days of Bu treatment
in the RIC setting, the risk of suboptimal Bu exposure is more
of a concern. Several previous studies describing condition-
ing regimens that used Bu and ﬂudarabine have reported a
high incidence of graft failure when the total Bu exposure
was low [43-47]. In our study, we observed a high rate of
graft failure in the ﬁrst patient cohort, who had a cumulative
Bu exposure of 8000 mMol*minute. The graft failure rate was
decreased signiﬁcantly in our second cohort, who had a cu-
mulative Bu exposure of 10,000 mMol*minute. The difference
in these rates suggested that an adequate Bu exposure is
necessary to prevent graft failure.
The use of cord blood also appeared to be a risk factor for
graft failure in our study. It has previously been shown thatthe use of cord blood was associated with a higher risk of
graft failure [48-51]. In our ﬁrst cohort, cord blood or pe-
ripheral blood were chosen on an equal footing as the source
of HPC, and the rate of graft failure was high. In the second
cohort, the protocol was modiﬁed so that cord blood was
used only when a peripheral blood HPC source was not
available. As a result, the use of cord blood was reduced,
coinciding with a decrease in the graft failure rate. Fisher
exact test analysis of patient subgroups conﬁrmed this
impression and showed an interaction between cord blood
use and Bu exposure. If cord blood were used, there was
a high risk of graft failure regardless of the level of Bu
exposure, whereas if nonecord blood was used, a low Bu
exposure was associated with graft failure. Thus, the use of
nonecord blood HPC source and the achievement of a
satisfactory Bu exposure both appear to be requisite for good
clinical outcome after RIC HPCT.
The results of our analysis suggest that the different levels
of Bu exposure and use of cord blood could account for the
contrasting clinical outcomes in our ﬁrst and second patient
cohorts, but we could not completely rule out the possibility
that other confounding factors could have contributed.
Importantly, the chronological times of treatment of the ﬁrst
and second cohorts were nonoverlapping. It is possible that
the patients in our second cohort had a better outcome
simply because they were treated in more recent years and
the experience of our team taking care of patients on this
protocol has improved. This and other questions can be
answered by further clinical trials that examine more infants
who are to receive HPCT using RIC regimens.
Although we have shown that the test doseebased
approach to optimize Bu exposure in infants is desirable, the
approach may not be feasible in all cases because of potential
logistical or cost considerations. Our data suggest an empir-
ical dosing strategy of the use of i.v. Bu at 4.5/kg/day for
2 days should provide a satisfactory Bu exposure to infants
undergoing RIC before HPCT.
To conclude, the use of ﬂudarabine, 2 single daily doses of
Bu, and ATG has been proven in our study to constitute an
effective and safe conditioning regimen in infants undergo-
ing HPCT for nonmalignant disorders.We found it valuable to
employ a test dose of i.v. Bu to guide the adjustment of the
single daily regimen doses of i.v. Bu. PK studies showed that
the clearance of the test dose correlated well with that of the
therapeutic dose in most of our patients. Engraftment
occurred in all but 1 patient in the second cohort, inwhich an
AUC of 5000 was targeted, compared with the 6 patients
(50%) who experienced either primary or secondary graft
failure in the ﬁrst cohort, in which an AUC of 4000 was tar-
geted. Thus, the increase in AUC target in this study of infants
with nonmalignant disorders improved outcomes related to
engraftment and OS without increasing toxicities.ACKNOWLEDGMENTS
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